World J Mens Health.  2016 Apr;34(1):28-33. 10.5534/wjmh.2016.34.1.28.

Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy

• Jeon JC
• Park J
• Park S
• Moon KH
• Cheon SH
• Park S

• KMID: 2162600
• DOI: http://doi.org/10.5534/wjmh.2016.34.1.28

Abstract

PURPOSE
The goal of this study was to investigate the association between hypercholesterolemia and the time required for progression to castration-resistant prostate cancer (CRPC) in patients who have undergone androgen deprivation therapy (ADT).
MATERIALS AND METHODS
Data from 154 patients with prostate cancer between 2005 and 2012 were reviewed retrospectively. ADT was employed as a treatment modality for these patients either due to multiple bone metastases at the time of diagnosis or due to old age in combination with other morbidities. Serum cholesterol levels and statin use were reviewed. We analyzed the factors associated with the development of CRPC after ADT treatment. The mean follow-up period was 34.8 months.
RESULTS
The mean age of the patients was 71.3 years old and their mean prostate-specific antigen level was 141.8±212.6 ng/mL. Their mean cholesterol level was 175.9±37.7 mg/dL, and 14 patients (9.1%) were statin users. CRPC developed in 44 patients (28.6%), and the mean duration from ADT treatment to CRPC was 24.1 months. In a multivariate analysis, hypercholesterolemia was associated with the development of CRPC (hazard ratio [HR]=1.017, p<0.001), depending on clinical T stage (p=0.005) and the presence of bone metastasis (p<0.001). A subanalysis showed that hypercholesterolemia was associated with the development of CRPC in patients with bone metastasis (HR=1.032, p<0.001), but not in patients without bone metastasis.
CONCLUSIONS
Hypercholesterolemia may be associated with the development of CRPC after ADT in patients with bone metastasis. Further studies with longer follow-up periods and larger samples are needed to validate this finding.

Keyword

Cholesterol; Prognosis; Prostatic neoplasms

MeSH Terms

Cholesterol
Diagnosis
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia*
Multivariate Analysis
Neoplasm Metastasis
Prognosis
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Retrospective Studies
Cholesterol
Prostate-Specific Antigen

Reference

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225–249. PMID: 19474385.

2. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol. 1999; 3:287–292. PMID: 10851335.

3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001; 1:34–45. PMID: 11900250.

4. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006; 9:379–385. PMID: 16778565.

5. Di Vizio D, Solomon KR, Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori. 2008; 94:633–639. PMID: 19112935.

6. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem. 2004; 91:54–69. PMID: 14689582.

7. Batty GD, Kivimäki M, Clarke R, Davey Smith G, Shipley MJ. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011; 22:311–318. PMID: 21116843.

8. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S. JPHC Study Group. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009; 125:2679–2686. PMID: 19544528.

9. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010; 21:61–68. PMID: 19806465.

10. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008; 123:1693–1698. PMID: 18646186.

11. Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol. 2006; 17:1014–1017. PMID: 16611646.

12. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011; 47:819–830. PMID: 21354784.

13. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17:27–36. PMID: 17944002.

14. Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer. 2010; 127:1650–1659. PMID: 20073066.

15. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006; 98:1819–1825. PMID: 17179483.

16. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16:2213–2217. PMID: 17971518.

17. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004; 22:537–556. PMID: 14752077.

18. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010; 116:3389–3398. PMID: 20586112.

19. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005; 162:318–325. PMID: 16014776.

20. Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Is statin use associated with prostate cancer aggressiveness? BJU Int. 2010; 105:1222–1225. PMID: 19888973.

21. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTPbinding proteins. Am J Cancer Res. 2011; 1:542–561. PMID: 21984972.

22. Schaffner CP. Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res. 1981; 75:279–324. PMID: 6175978.

23. Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta. 2013; 1835:219–229. PMID: 23357067.

24. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010; 28:2653–2659. PMID: 20421534.